Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma

Abstract

Adoptive cellular immunotherapy with HERV-K env-specific CAR(+) T cells represents a clinically appealing treatment strategy for advanced-stage melanoma and provides an approach for targeting this TAA on other solid tumors.